Last reviewed · How we verify
AGSAVI
AGSAVI is an investigational therapeutic agent in Phase 3 development by Ahn-Gook Pharmaceuticals, but its specific mechanism of action is not publicly disclosed.
At a glance
| Generic name | AGSAVI |
|---|---|
| Also known as | S-amlodipine, Valsartan, Indapamide |
| Sponsor | Ahn-Gook Pharmaceuticals Co.,Ltd |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without access to detailed clinical trial data or published mechanism information for AGSAVI, the precise molecular target and pharmacological action cannot be reliably determined. Phase 3 status indicates the drug has progressed through earlier safety and efficacy testing, but mechanism details remain proprietary or unpublished.
Approved indications
Common side effects
Key clinical trials
- Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS (PHASE3)
- Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGSAVI CI brief — competitive landscape report
- AGSAVI updates RSS · CI watch RSS
- Ahn-Gook Pharmaceuticals Co.,Ltd portfolio CI